RhumbLine Advisers’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.3M Buy
118,420
+2,668
+2% +$119K ﹤0.01% 1471
2025
Q4
$5.39M Sell
115,752
-15,770
-12% -$702K ﹤0.01% 1361
2025
Q3
$5.48M Sell
131,522
-3,785
-3% -$121K ﹤0.01% 1382
2025
Q2
$3.89M Buy
135,307
+3,357
+3% +$104K ﹤0.01% 1543
2025
Q1
$4.43M Buy
131,950
+7,872
+6% +$294K ﹤0.01% 1419
2024
Q4
$6.34M Buy
124,078
+15,359
+14% +$859K 0.01% 1305
2024
Q3
$5.56M Sell
108,719
-3,600
-3% -$186K 0.01% 1374
2024
Q2
$5.03M Buy
112,319
+3,626
+3% +$167K ﹤0.01% 1395
2024
Q1
$5.09M Buy
108,693
+1,478
+1% +$57.8K ﹤0.01% 1411
2023
Q4
$3.81M Buy
107,215
+661
+0.6% +$20.3K ﹤0.01% 1574
2023
Q3
$3.17M Buy
106,554
+16,400
+18% +$338K ﹤0.01% 1606
2023
Q2
$1.62M Buy
90,154
+8,250
+10% +$165K ﹤0.01% 2021
2023
Q1
$1.31M Buy
81,904
+2,916
+4% +$54K ﹤0.01% 2011
2022
Q4
$1.45M Sell
78,988
-7
-0% -$123 ﹤0.01% 1948
2022
Q3
$1.55M Buy
78,995
+5,439
+7% +$111K ﹤0.01% 1902
2022
Q2
$1.37M Buy
73,556
+25,855
+54% +$516K ﹤0.01% 1965
2022
Q1
$1.05M Buy
47,701
+4,654
+11% +$94.2K ﹤0.01% 2113
2021
Q4
$1.22M Buy
43,047
+7,644
+22% +$188K ﹤0.01% 2125
2021
Q3
$745K Buy
35,403
+1,852
+6% +$38.7K ﹤0.01% 2362
2021
Q2
$632K Buy
33,551
+5,154
+18% +$90.6K ﹤0.01% 2449
2021
Q1
$434K Sell
28,397
-2,370
-8% -$36.7K ﹤0.01% 2556
2020
Q4
$434K Buy
30,767
+2,780
+10% +$38.7K ﹤0.01% 2495
2020
Q3
$439K Sell
27,987
-4,670
-14% -$71.4K ﹤0.01% 2345
2020
Q2
$572K Buy
32,657
+19,959
+157% +$340K ﹤0.01% 2280
2020
Q1
$187K Hold
12,698
﹤0.01% 2612
2019
Q4
$319K Buy
12,698
+72
+0.6% +$1.37K ﹤0.01% 2562
2019
Q3
$190K Sell
12,626
-125
-1% -$2.43K ﹤0.01% 2761
2019
Q2
$319K Buy
12,751
+2,975
+30% +$73.7K ﹤0.01% 2577
2019
Q1
$223K Buy
9,776
+1,301
+15% +$32K ﹤0.01% 2705
2018
Q4
$254K Buy
+8,475
New +$239K ﹤0.01% 2617

Other funds holding CRNX